Kobak, ŞenolOrman, Mehmet Akif2020-08-302020-08-302017Kobak, S., & Orman, M. (2017). SAT0476 Demographic, clinical, and laboratory characteristics of elderly onset psoriatic arthritis.0003-49671468-2060https://doi.org/10.1136/annrheumdis-2017-eular.1378https://hdl.handle.net/20.500.12713/893Annual European Congress of Rheumatology -- JUN 14-17, 2017 -- Madrid, SPAINBackground: Psoriatic arthritis (PsA) is a chronic in?amatory disease characterized with axial and peripheral joints involvement. It is rarely affects patients older than 65 years old. Objectives: The purpose of this study is to compare and evaluate the demographic,clinicalandlaboratoryfeaturesofelderly-onsetpsoriaticarthritis(EOPsA) and young-onset (YOPsA) patients. Methods: One hundred and eighty patients diagnosed with PsA according to CASPAR criteria and followed-up in single center were included in this study. The patients with initial symptoms started after age 65 were accepted as EOPsA. Demographic,clinical,andlaboratorydataandthemedicationswhichthepatients recieved were recorded and retrospectively evaluated. Results: Nineteen (10.5%)of 180 patients were diagnosed as EOPsA, and 161 (89.5%) patients were evaluated as YOPsA. Mean patient age was 42.1years for YOPsA group and 68.3years for elderly onset group. Mean duration of disease was 5.6 years for early onset group and 1.3 years for elderly onset group (p=0.001). Fourteen (73.3%) of 19 EOPsA patients were female and 5 of them were male. Higher rates of fatique, pain scores, comorbid diseases and acute phase reactants were detected in EOPsA patients comparing to YOPsA (p=0.000, p=0.000, p=0.001 and p=0.001 respectively). YOPsA patients have more dactilitis, nail involvement, elevated PASI scores, and smoking habitus when comparedwithEOPsApatients(p=0.019,p=0.03,p=0.005,p=0.004respectively). In terms of the treatment options chosen, there was no signi?cant difference in the use of non-steroidal anti-in?ammatory drugs (NSAIDs), corticosteroids (CS), methotrexate (MTX), and sulfasalazine (SSL), but there was a more frequent use of anti-tumor necrosis factor -alpha in YOPsA group. Conclusions: Herein we showed that YOPsA and EOPsA patients may have different demographic, clinical, and laboratory features. EOPsA patients are characterized with higher rates of fatique, pain scores, comorbid diseases, and acute phase reactants and less dactilitis, nail involvement and anti-TNF-alpha usage.eninfo:eu-repo/semantics/openAccessConference Object76955955WOS:000413181402762Q110.1136/annrheumdis-2017-eular.1378